Organic cation transporter 1 mediates the uptake of monocrotaline and plays an important role in its hepatotoxicity

Toxicology

Volumn 311, Issue 3, 2013, Pages 225-230

  Tu, Meijuan ^a   Sun, Siyuan ^a   Wang, Kai ^a   Peng, Xueying ^a   Wang, Ruihan ^a   Li, Liping ^a   Zeng, Su ^a   Zhou, Hui ^a   Jiang, Huidi ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Hepatotoxicity; Liver; Monocrotaline; OCT1; Uptake

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; DEXTRO TETRAHYDROPALMATINE; LACTATE DEHYDROGENASE; MONOCROTALINE; ORGANIC CATION TRANSPORTER 1; QUINIDINE SULFATE; TETRAHYDROPALMATINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL CULTURE; CELL ISOLATION; CELL TRANSPORT; CONTROLLED STUDY; ENZYME RELEASE; IC 50; INHIBITION KINETICS; LIVER CELL; LIVER TOXICITY; MALE; MDCK CELL; MICHAELIS MENTEN KINETICS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TRANSPORT KINETICS;

1-METHYL-4-PHENYLPYRIDINIUM; 2-(N-MORPHOLINO)ETHANESULFONIC ACID; 4-(4-(DIMETHYLAMINO)STYRYL)-N-METHYLPYRIDINIUM; ASP(+); CYP; CYTOCHROME P450; D-TETRAHYDROPALMATINE; D-THP; DEHYDROMONOCROTALINE; DHM; DIMETHYL SULFOXIDE; DMSO; HANK'S BALANCED SALT SOLUTION; HBSS; HEPATOTOXICITY; LIVER; MADIN-DARBY CANINE KIDNEY; MCT; MDCK; MES; MONOCROTALINE; MPP+; OCT1; ORGANIC CATION TRANSPORTER 1; PAS; PYRROLIZIDINE ALKALOIDS; SDS; SODIUM DODECYL SULFONATE; TEA; TETRAETHYLAMMONIUM; UPTAKE;

1-METHYL-4-PHENYLPYRIDINIUM; ANIMALS; BIOLOGICAL TRANSPORT; CELL SURVIVAL; CELLS, CULTURED; DOGS; HEPATOCYTES; HUMANS; L-LACTATE DEHYDROGENASE; MADIN DARBY CANINE KIDNEY CELLS; MALE; MONOCROTALINE; ORGANIC CATION TRANSPORTER 1; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84882687048     PISSN: 0300483X     EISSN: 18793185     Source Type: Journal    
DOI: 10.1016/j.tox.2013.06.009     Document Type: Article

References (42)

1. Ahlin G., Hilgendorf C., Karlsson J., Szigyarto C.A.K., Uhlén M., Artursson P. Endogenous gene and protein expression of drug-transporting proteins in cell lines routinely used in drug discovery programs. Drug Metab. Dispos. 2009, 37:2275-2283.
2. Ahlin G., Karlsson J., Pedersen J.M., Gustavsson L., Larsson R., Matsson P., Norinder U., Bergstrom C.A., Artursson P. Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1. J. Med. Chem. 2008, 51:5932-5942.
3. Barreto R., Sousa C., Silva V., Silva A., Veloso E., Cunha S., Costa M., El-Bachá R., Costa S. Monocrotaline pyrrol is cytotoxic and alters the patterns of GFAP expression on astrocyte primary cultures. Toxicol. Vitro 2008, 22:1191-1197.
4. Boppre M. The ecological context of pyrrolizidine alkaloids in food, feed and forage: an overview. Food Addit. Contam. Part A 2011, 28:260-281.
5. Copple B.L., Banes A., Ganey P.E., Roth R.A. Endothelial cell injury and fibrin deposition in rat liver after monocrotaline exposure. J. Toxicol. Sci. 2002, 65:309-318.
6. Copple B.L., Rondelli C.M., Maddox J.F., Hoglen N.C., Ganey P.E., Roth R.A. Modes of cell death in rat liver after monocrotaline exposure. J. Toxicol. Sci. 2004, 77:172-182.
7. DeLeve L.D., McCuskey R.S., Wang X., Hu L., McCuskey M.K., Epstein R.B., Kanel G.C. Characterization of a reproducible rat model of hepatic veno-occlusive disease. Hepatology 2003, 29:1779-1791.
8. Fu P.P., Xia Q., Lin G., Chou M.W. Pyrrolizidine alkaloids-genotoxicity, metabolism enzymes, metabolic activation, and mechanisms. Drug Metab. Rev. 2004, 36:1-55.
9. Gomez-Lechon M., Donato M., Castell J., Jover R. Human hepatocytes as a tool for studying toxicity and drug metabolism. Curr. Drug Metab. 2003, 4:292-312.
10. Gomez-Lechon M., Donato M., Lahoz A., Castell J. Cell lines: a tool for in vitro drug metabolism studies. Curr. Drug Metab. 2008, 9:1-11.
11. Gomez-Lechon M., Lahoz A., Gombau L., Castell J., Donato M. In vitro evaluation of potential hepatotoxicity induced by drugs. Curr. Pharm. Des. 2010, 16:1963-1977.
12. Guidance for Industry Drug interaction studies: study design, data analysis and implications for dosing and labeling recommendations 2012, http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf.
13. Gründemann D., Hahne C., Berkels R., Schömig E. Agmatine is efficiently transported by non-neuronal monoamine transporters extraneuronal monoamine transporter (EMT) and organic cation transporter 2 (OCT2). J. Pharmacol. Exp. Ther. 2003, 304:810-817.
14. Hansen M.B., Nielsen S.E., Berg K. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J. Immunol. Methods 1989, 119:203.
15. Hewitt N.J., Gómez Lechón M.J., Houston J.B., Hallifax D., Brown H.S., Maurel P., Kenna J.G., Gustavsson L., Lohmann C., Skonberg C. Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab. Rev. 2007, 39:159-234.
16. Ji L.L., Zhao X.G., Chen L., Zhang M., Wang Z.T. Pyrrolizidine alkaloid clivorine inhibits human normal liver L-02 cells growth and activates p38 mitogen-activated protein kinase in L-02 cells. Toxicon 2002, 40:1685-1690.
17. Koepsell H., Endou H. The SLC22 drug transporter family. Pflugers Arch. 2004, 447:666-676.
18. Koepsell H., Schmitt B., Gorboulev V. Organic cation transporters. Ergeb. Physiol. 2003, 150:36-90.
19. Lamé M.W., Jones A.D., Wilson D.W., Segall H. Monocrotaline pyrrole targets proteins with and without cysteine residues in the cytosol and membranes of human pulmonary artery endothelial cells. Proteomics 2005, 5:4398-4413.
20. Liguori M.J., Blomme E.A.G., Waring J.F. Trovafloxacin-induced gene expression changes in liver-derived in vitro systems: comparison of primary human hepatocytes to HepG2 cells. Drug Metab. Dispos. 2008, 36:223-233.
21. Lin G., Zhou K.Y., Zhao X.G., Wang Z.T., But P.P.H. Determination of hepatotoxic pyrrolizidine alkaloids by on line high performance liquid chromatography mass spectrometry with an electrospray interface. Rapid Commun. Mass Spectrom. 1998, 12:1445-1456.
22. Lu X., Sun D., Chen Z., Ye J., Wang R., Li L., Zeng S., Jianga H. Evaluation of hepatic clearance and drug-drug interactions of luteolin and apigenin by using primary cultured rat hepatocytes. Pharmazie 2011, 66:600-605.
23. McLean E.K. The toxic actions of pyrrolizidine (Senecio) alkaloids. Pharmacol. Rev. 1970, 22:429-483.
24. Meyer-Wentrup F., Karbach U., Gorboulev V., Arndt P., Koepsell H. Membrane localization of the electrogenic cation transporter rOCT1 in rat liver. Biochem. Biophys. Res. Commun. 1998, 248:673-678.
25. Mingatto F.E., Dorta D.J., dos Santos A.B., Carvalho I., da Silva C.H.T.P., da Silva V.B., Uyemura S.A., dos Santos A.C., Curti C. Dehydromonocrotaline inhibits mitochondrial complex I. A potential mechanism accounting for hepatotoxicity of monocrotaline. Toxicon 2007, 50:724-730.
26. Nakamura K., Hatano E., Narita M., Miyagawa-Hayashino A., Koyama Y., Nagata H., Iwaisako K., Taura K., Uemoto S. Sorafenib attenuates monocrotaline-induced sinusoidal obstruction syndrome in rat through suppression of JNK and MMP-9. J. Hepatol. 2012, 57:1037-1043.
27. Nies A.T., Herrmann E., Brom M., Keppler D. Vectorial transport of the plant alkaloid berberine by double-transfected cells expressing the human organic cation transporter 1 (OCT1, SLC22A1) and the efflux pump MDR1 P-glycoprotein (ABCB1). Naunyn Schmiedebergs Arch. Pharmacol. 2008, 376:449-461.
28. Nies A.T., Koepsell H., Damme K., Schwab M. Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy. Handb. Exp. Pharmacol. 2011, 105-167.
29. Nies A.T., Koepsell H., Winter S., Burk O., Klein K., Kerb R., Zanger U.M., Keppler D., Schwab M., Schaeffeler E. Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology 2009, 50:1227-1240.
30. Nobre V.M.T., Riet-Correa F., Barbosa Filho J.M., Dantas A.F.M., Tabosa I.M., Vasconcelos J.S. Poisoning by Crotalaria retusa (Fabaceae) in Equidae in the semiarid region of Paraíba. Pesqui. Vet. Bras. 2004, 24:132-143.
31. Okuda M., Urakami Y., Saito H., Inui K. Molecular mechanisms of organic cation transport in OCT2-expressing Xenopus oocytes. Biochim. Biophys. Acta. Biomembr. 1999, 1417:224-231.
32. Saadatmand A.R., Tadjerpisheh S., Brockmöller J., Tzvetkov M.V. The prototypic pharmacogenetic drug debrisoquine is a substrate of the genetically polymorphic organic cation transporter OCT1. Biochem. Pharmacol. 2012, 83:1427-1434.
33. Santos A.B., Dorta D.J., Pestana C.R., Maioli M.A., Curti C., Mingatto F.E. Dehydromonocrotaline induces cyclosporine A-insensitive mitochondrial permeability transition/cytochrome c release. Toxicon 2009, 54:16-22.
34. Schoental R., Head M.A. Pathological changes in rats as a result of treatment with monocrotaline. Br. J. Cancer 1955, 9:229-237.
35. Shu Y., Leabman M.K., Feng B., Mangravite L.M., Huang C.C., Stryke D., Kawamoto M., Johns S.J., DeYoung J., Carlson E. Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:5902-5907.
36. Sun S.Y., Wang Y.Q., Li L.P., Wang L., Zeng S., Zhou H., Jiang H.D. Stereoselective interaction between tetrahydropalmatine enantiomers and cyp enzymes in human liver microsomes. Chirality 2012, 25:43-47.
37. Urakami Y., Akazawa M., Saito H., Okuda M., Inui K. cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney. J. Am. Soc. Nephrol. 2002, 13:1703-1710.
38. Urakami Y., Okuda M., Masuda S., Saito H., Inui K.I. Functional characteristics and membrane localization of rat multispecific organic cation transporters, OCT1 and OCT2, mediating tubular secretion of cationic drugs. J. Pharmacol. Exp. Ther. 1998, 287:800-805.
39. Wang Y.P., Yan J., Beger R.D., Fu P.P., Chou M.W. Metabolic activation of the tumorigenic pyrrolizidine alkaloid, monocrotaline, leading to DNA adduct formation in vivo. Cancer Lett. 2005, 226:27-35.
40. Yan C.C., Huxtable R.J. The effect of the pyrrolizidine alkaloids, monocrotaline and trichodesmine, on tissue pyrrole binding and glutathione metabolism in the rat. Toxicon 1995, 33:627-634.
41. Yan C.C., Huxtable R.J. The relationship between the concentration of the pyrrolizidine alkaloid monocrotaline and the pattern of metabolites released from the isolated liver. Toxicol. Appl. Pharmacol. 1995, 130:1-8.
42. +) in mouse striatal tissue. J. Chromatogr. B 2008, 874:51-56.